Models of prophylaxis

Haemophilia

Volumn 18, Issue SUPPL.4, 2012, Pages 136-140

  Berntorp, Erik ^a   Fischer, Kathelijn ^b   Miners, Alec ^c  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Bleeding; FIX; FVIII; Haemophilia; Outcome; Prophylaxis

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9;

ARTICLE; BLEEDING; COST EFFECTIVENESS ANALYSIS; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG DOSE REGIMEN; DRUG MEGADOSE; HEMOPHILIA A; HEMOPHILIA B; HUMAN; LONG TERM CARE; MODEL; NETHERLANDS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOCIOECONOMICS; SWEDEN; TREATMENT DURATION; TREATMENT INDICATION;

CLINICAL TRIALS AS TOPIC; COAGULANTS; DRUG ADMINISTRATION SCHEDULE; FACTOR IX; FACTOR VIII; HEMOPHILIA A; HEMOPHILIA B; HUMANS; MODELS, BIOLOGICAL; NETHERLANDS; SWEDEN;

EID: 84862905973     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2012.02839.x     Document Type: Article

References (26)

1. Ramgren O. A clinical and medico-social study of haemophilia in Sweden. Acta Med Scand Suppl. 1962; 379: 111-90.
2. Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand Suppl 1965: Suppl. 77: 3-132.
3. Van Creveld S. Prophylaxis of joint hemorrhages in hemophilia. Acta Haematol 1971; 45: 120-7.
4. Kasper CK, Dietrich SL, Rapaport SI. Hemophilia prophylaxis with factor VIII concentrate. Arch Intern Med 1970; 125: 1004-9.
5. Aronstam A, Arblaster PG, Rainsford SG et al. Prophylaxis in haemophilia: a double-blind controlled trial. Br J Haematol 1976; 33: 81-90.
6. Schimpf K, Fischer B, Rothmann P. [A controlled study of treating haemophilia A on an out-patient basis (author's transl)]. Dtsch Med Wochenschr 1976; 101: 141-8. Die ambulante Dauerbehadnlung der Hamophilie A. Eine kontrollierte Studie.
7. Morfini M, Mannucci PM, Mariani G et al. Evaluation of prophylactic replacement therapy in haemophilia B. Scand J Haematol. 1976; 16: 41-7.
8. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
9. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391-9.
10. Steen Carlsson K, Hojgard S, Glomstein A et al. On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome. Haemophilia 2003; 9: 555-66.
11. Chambost H, Ljung R. Changing pattern of care of boys with haemophilia in western European centres. Haemophilia 2005; 11: 92-9.
12. Feldman BM, Funk S, Lundin B, Doria AS, Ljung R, Blanchette V. Musculoskeletal measurement tools from the International Prophylaxis Study Group (IPSG). Haemophilia 2008; 14(Suppl. 3): 162-9.
13. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
14. Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9: 700-10.
15. Berntorp E, Astermark J, Baghaei F et al. Treatment of haemophilia A and B and von Willebrand's disease: summary and conclusions of a systematic review as part of a Swedish health-technology assessment. Haemophilia 2012; 18: 158-65.
16. Fischer K, Astermark J, van der Bom JG et al. Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. Haemophilia 2002; 8: 753-60.
17. Auerswald G, Bidlingmaier C, Kurnik K. Early prophylaxis/FVIII tolerization regimen that avoids immunological danger signals is still effective in minimizing FVIII inhibitor developments in previously untreated patients - long-term follow-up and continuing experience. Haemophilia 2012; 18: e18-20.
18. Pettersson H, Nilsson IM, Hedner U, Norehn K, Ahlberg A. Radiologic evaluation of prophylaxis in severe haemophilia. Acta Paediatr Scand. 1981; 70: 565-70.
19. Gilbert MS. Prophylaxis: Musculoskeletal evaluation. Semin Hematol 1993; 30: 3-6.
20. Fischer K, Grobbee DE, van den Berg HM. RCTs and observational studies to determine the effect of prophylaxis in severe haemophilia. Haemophilia 2007; 13: 345-50.
21. Erlemann R, Rosenthal H, Walthers EM, Almeida P, Calleja R. Reproducibility of the pettersson scoring system. An interobserver study. Acta Radiol 1989; 30: 147-51.
22. Hilliard P, Funk S, Zourikian N et al. Hemophilia joint health score reliability study. Haemophilia 2006; 12: 518-25.
23. Beeton K, De Kleijn P, Hilliard P et al. Recent developments in clinimetric instruments. Haemophilia 2006; 12(Suppl. 3): 102-7.
24. Craig CL, Marshall AL, Sjostrom M et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 2003; 35: 1381-95.
25. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001; 33: 337-43.
26. Culyer AJ, Bombard Y. An equity framework for health technology assessments. Med Decis Making 2011; doi: 10.1177/027989X11426484.